Latest Breaking News On - Energous wattup - Page 6 : comparemela.com
Energous (NASDAQ:WATT) - Energous Launches Active Energy Harvesting Developer Kit For Over-The-Air Wireless Charging
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Thinfilm and Energous Announce Partnership to Enable Ultrathin, Reliable, Wirelessly Rechargeable Devices – Consumer Electronics Net
consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
Energous Corporation: Thinfilm and Energous Announce Partnership to Enable Ultrathin, Reliable, Wirelessly Rechargeable Devices
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Xiaomi Mi Air Charge, the new completely remote charging system
explica.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from explica.co Daily Mail and Mail on Sunday newspapers.
Immunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event
Immunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 13
th Annual Biotech Showcase Digital Event, January 11-15, 2021. Chief Executive Officer at ITI, Dr. Bill Hearl, will present a talk titled, ITI-1000-A Novel Immunotherapy for GBM. Dr. Hearl will discuss ITIs investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology, specifically glioblastoma multiforme (GBM). ITIs technology platform has the potential to utilize the bodys natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.